AIkido Pharma Inc. (NASDAQ:AIKI) changed 21.99% to recent value of $1.04. The stock transacted 188532912 shares during most recent day however it has an average volume of 6.72M shares. It spotted trading -80.95% off 52-week high price. On the other end, the stock has been noted 123.37% away from the low price over the last 52-weeks.
On Jan. 6, 2021, AIkido Pharma Inc. (NASDAQ:AIKI) released that the Company executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. The technology is covered by four patent applications already on file with the United States Patent and Trademark Office.
Psilocybin is a naturally occurring psychedelic compound. Research has shown psilocybin to have potential to treat a range of psychiatric and behavioral disorders, notably, cancer-related depression and anxiety. The use of psilocybin to treat cancer patients is a growing field. Studies by such notable institutions as Johns Hopkins and NYU Grossman School of Medicine found that one-time, single-dose treatments of psilocybin, combined with psychotherapy, appears to be associated with significant improvements in emotional distress in people with cancer and that these effects persisted nearly five years after the drug was administered.
Mr. Anthony Hayes, CEO of AIkido, stated, We are excited to explore this aspect of cancer treatment. Our license covers the use of psilocybin to treat both cancer and cancer side-effects and we believe this to be an expanding area for treatment.
Its earnings per share (EPS) expected to touch remained -282.90% for this year.
The company has 34.99M of outstanding shares and 32.96M shares were floated in the market. According to the most recent quarter its current ratio was 59.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 51.46% from the mean of 20 days, 74.80% from mean of 50 days SMA and performed 46.21% from mean of 200 days price. Company’s performance for the week was 65.11%, 64.56% for month and YTD performance remained 19.06%.